Indian Journal of Dermatology
CASE REPORT
Year
: 2020  |  Volume : 65  |  Issue : 6  |  Page : 522--525

Hand-foot skin reaction with sunitinib: A rare case report with review of literature


Suchibrata Das, Alok K Roy, Srutee Barman, Aritra Roy 
 Department of Dermatology, Venereology and Leprosy, NRS Medical College, 138 AJC Bose Road, Kolkata, West Bengal, India

Correspondence Address:
Suchibrata Das
Department of Dermatology, Venereology and Leprosy, NRS Medical College, 138 AJC Bose Road, Kolkata, West Bengal - 700 014
India

Abstract

Newer multi-kinase inhibitors (MKI) like sunitinib have changed the therapy of patients of renal cell carcinoma, hepatocellular carcinoma, and gastrointestinal stromal tumor. The use of sunitinib also led to cutaneous toxicity, known as hand-foot skin reaction (HFSR). We report a case of hand-foot skin reaction (HFSR) in an Indian patient being treated with sunitinib. Respective literature on this disorder is also reviewed.



How to cite this article:
Das S, Roy AK, Barman S, Roy A. Hand-foot skin reaction with sunitinib: A rare case report with review of literature.Indian J Dermatol 2020;65:522-525


How to cite this URL:
Das S, Roy AK, Barman S, Roy A. Hand-foot skin reaction with sunitinib: A rare case report with review of literature. Indian J Dermatol [serial online] 2020 [cited 2021 Jan 17 ];65:522-525
Available from: https://www.e-ijd.org/text.asp?2020/65/6/522/298920


Full Text



 Introduction



Adverse cutaneous drug reactions (ACDR) are common in dermatological practice. There are a plethora of newer anticancer drugs though there is limited information on adverse effects of them.

Sunitinib is one of the newer multi-kinase inhibitors (MKI), an important inhibitor of tumor angiogenesis, a selective inhibitor of vascular endothelial growth factor receptor (VEGFR)-2 and VEGFR-3, platelet-derived growth factor receptor (PDGFR)-β, Raf, FLT-3, and C- kit.[1] It is approved mainly for renal cell carcinoma, hepatocellular carcinoma, and gastrointestinal stromal tumor.[2]

The use of sunitinib also led to cutaneous toxicity, known as hand-foot skin reaction (HFSR), which differs from the hand-foot syndrome (HFS), which is caused by many older cytotoxic drugs.[3] There are few reports stating that sunitinib can produce a hand-foot skin reaction, but the occurrence of that in Indian subcontinent is rare. We report a case of hand-foot skin reaction (HFSR) in an Indian patient being treated with sunitinib. Respective literature on this disorder is also reviewed.

 Case Report



A 58-year-old male patient presented in the outpatient with a complaint of eruptions with pain and burning sensation of extremities. He had multiple tender and painful blisters and hyperkeratotic plaques on palms and soles. Yellow-colored callus-like hyperkeratotic plaques were present on the undersurface of the great toes [Figure 1]a, [Figure 1]b, at the palmer aspect of 4th metacarpophalangeal joint [Figure 2]a. Blisters were on sides of 2nd toes and dorsum of one foot - sites likely had friction with chappal footwear [Figure 1]c. Blisters were surrounded by erythema [Figure 1]d. He had ulcerated and crusted lesions on extensor of elbows [Figure 2]c, on dorsum of foot [Figure 1]c, at lower back just above the gluteal cleft, and mucosal lesions involving angles of the mouth (like angular cheilitis).{Figure 1}{Figure 2}

The patient had metastatic renal cell carcinoma for that he was on sunitinib therapy. Treatment with sunitinib started 1 month back, 37.5 mg daily for two weeks followed by 50 mg daily. Ten days after dose escalation, these lesions developed and gradually increased in number. The patient complained of pain and burning sensation of limbs also. He was not taking any other drug regularly.

His hemoglobin was 9.5 g%, serum urea was 54.2 mg, and uric acid was 7.90 mg, other parameters were within normal limits. Based on the history and clinical examination, a diagnosis of hand-foot skin reaction (HFSR) was made. Other differential diagnoses were erythromelalgia, graft-versus-host disease, chemotherapy-induced Raynaud's syndrome, erythema multiforme, and other cutaneous drug reactions. We were unable to perform a biopsy as the patient's condition didn't permit. Also, we were unable to do a rechallenge test as the patient did not give consent or was not admitted to our indoor patient department.

He was advised for dose reduction of sunitinib. Also, advised to avoid friction, given vitamin B-complex, topical antibiotics, paraffin, and betamethasone oint. All the lesions became less within 14 days with above management with improvement of physical discomfort also [Figure 3]a, [Figure 3]b, [Figure 3]c, [Figure 3]d, [Figure 3]e.{Figure 3}

 Discussion



In hand-foot syndrome caused by traditional chemotherapeutic drugs like 5FU, doxorubicin,[3] or capecitabine (28%–74%), docetaxel, etc.,[3] there is a prodrome of dysesthesia in most of the patients that progresses to a burning pain (which may be severe) followed by well-defined swelling and erythema. The symmetric erythema is more marked over the pads of the distal phalanges. The hands are usually more severely affected than the feet, and rarely, outside the palmer and plantar regions with fine desquamation. Lesions worsen with continued therapy, and after withdrawal, a gradual clearing of symptoms occurs over a period of 2 weeks.[3]

Two new drugs, of multi targeted kinase inhibitor group, sorafenib and sunitinib, have emerged as significant causes of HFS.[3] Here disease is more likely to present as localized patches not only on pressure-bearing aspects of the palms and soles but also on areas that rub against neighboring surfaces, such as the lateral soles and web spaces, in comparison with traditional HFS.[4] Male and female genital involvement is also noted.[5] Several patients on multi targeted kinase inhibitors also developed simultaneous scalp dysesthesia, angular cheilitis, perianal rashes, and facial erythema resembling seborrheic dermatitis, although it was unclear whether these rashes shared common pathogenesis with the concomitant HFS.[3] A bullous variant probably represents a severe form of the syndrome.[3] This group of features coined a separate name—hand-foot skin reaction (HFSR).[4] Our patient developed dysesthesia at the beginning, followed by blisters with surrounding erythema, callus-like blister, or hyperkeratotic plaque. He had lesions on pressure points (sole of feet, elbow), at the same time in areas of friction i.e., sides of toes, undersurface of fingers [Figure 1]c, [Figure 1]d, [Figure 2]a. In addition to that, he had angular cheilitis also [Figure 2]d. Lesions on feet were more than on hands, as opined for HFSR caused by sunitinib[3]

Different clinical presentations lead to the discussion of different mechanisms for development of hand foot skin reaction and HFS, one of them is the excretion of the drug through the sweat glands that leads to a high concentration in the areas of the skin around the sweat glands.[4] But significant levels of kinase-inhibitor may not be present in sweat collected from patients' palms.[6] Another theory is hand-foot skin reaction due to multi kinase inhibitor (MKI) may be caused by drug leakage from capillaries damaged by subclinical trauma.[7] This hypothesis was backed by observation like lesions on fingertips produced by the friction of Blackberry handheld device.[8] Our patient also had blisters on the friction areas of footwear or joints.

The diagnosis of HFSR is usually made from the clinical presentation, in those patients with a history of taking MKI drugs.[3]

Time of onset of HFSR is usually between 3–6 weeks of treatment.[3] Our patient also developed lesions near the end of the fourth week. By the Adverse Drug Reaction (ADR) Probability Scale (Naranjo scale), the causality of using sunitinib and the development of HFSR in our patient is probable (score 5).

According to The National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 (NCI-CTCAE v 4.0)[9] severity of HFSR is up to Grade 3, not life-threatening and is reversible [Table 1].{Table 1}

Using this terminology is helpful in guiding therapeutic decisions as well as communicating with the treating oncologist.

HFSR can significantly impact the quality of life (QoL). For that, dose modification or treatment discontinuation may be required. Furthermore, continuous MKI treatment in Grade 1 or 2 toxicities can progress to Grade 3. So, it is required for clinicians to closely monitor patients receiving MKI with HFSR and be aware of prevention and management strategies that may reduce its incidence, duration, and severity.[10]

Recommendations for treatment are as follows [Table 2]-[11]{Table 2}

Plantar hyperkeratosis is a putative risk factor for HFSR, and controlling them with adequate foot care may help to reduce the development of HFSR,[12] though the debatable, prophylactic application of exfoliating products to the calluses and prophylactic pyridoxine (vitamin B) are in use.[13]

HFSR due to sunitinib is rarely reported from India and to our knowledge, it is the first case of bullous lesion with HFSR patient from India. The incidence of the development of such severe skin reaction is high in the phase III clinical trial, but data from the Indian context is rare.

Patients taking medications that have propensity to develop HFSR should be informed for the potential development of this condition. Awareness about the probability of such reactions helps to counter/prevent/minimize the distressing condition.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References

1Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, et al .In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9:327-37.
2Rock EP, Goodman V, Jiang JX, Mahjoob K, Verbois SL, Morse D, et al. Food and drug administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist 2007;12:107-13.
3Lipworth AD, Robert C, Zhu AX. Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib. Oncology 2009;77:257-71.
4Yang CH, Lin WC, Chuang CK, Chang YC, Pang ST, Lin YC, et al . Hand-foot skin reaction in patients treated with sorafenib: A clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy. Br J Dermatol 2008;158:592-6.
5Iacovelli R, Mancini ML, Risi E, Palazzo A, Cortesi E. Genital and inguinal cutaneous toxicity in male and female patients treated with Sunitinib. Int J Dermatol 2012;51:221-2.
6Jain L, Gardner ER, Figg WD, Chernick MS, Kong HH. Lack of association between excretion of sorafenib in sweat and hand–foot skin reaction. Pharmacotherapy 2010;30:52-6.
7Sibaud V, Delord J, Chevreau C. Sorafenib-induced hand–foot skin reaction: A Koebner phenomenon? Targ Oncol 2009;4:307.
8Boone SL, Jameson G, von Hoff D, Lacouture ME. Blackberry-induced hand–foot skin reaction to Sunitinib. Invest New Drugs 2009;27:389-90.
9National Cancer Institute, National Institutes of Health, US Department of Health and Human Services. Common Terminology Criteria Adverse Events (CTCAE) Version 4.02. NIH publication 03-5410. Bethesda, MD: National Institutes of Health; 2009.
10Gomez P, Lacouture ME. Clinical presentation and management of hand–foot skin reaction associated with sorafenib in combination with cytotoxic chemotherapy: Experience in breast cancer. Oncologist 2011;16:1508-19.
11McLellan B, Kerr H. Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib. Dermatol Ther 2011;24:396-400.
12Webster-Gandy JD, How C, Harrold K. Palmar-plantar erythrodysesthesia (PPE): a literature review with commentary on experience in a cancer centre. Eur J Oncol Nurs 2007;11:238-46.
13Anderson R, Jatoi A, Robert C, Wood LS, Keating KN, Lacouture ME. Search for evidence-based approaches for the prevention and palliation of hand–foot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs). Oncologist 2009;14:291-302.